Visual Impairment in Children with Epilepsy Treated with Vigabatrin
Ann Neurol 48:60-64, Gross-Tsur,V. et al, 2000
A Man Who Lost Weight and His Sight
Lancet 351:1174-1175, Moschos,M.&Droutsas,D., 1998
Neurosarcoidosis:Signs, Course and Treatment in 35 Confirmed Cases
Medicine 69:261-276, Chapelon,C.,et al, 1990
Cortical Blindness:Etiology, Diagnosis, & Prognosis
Ann Neurol 21:149-158, Aldrich,M.S.,et al, 1987
Carotid Occlusive Disease, Effect of Bright Light on Visual Evoked Response
Arch Neurol 39:687-689, Donnan,G.A.,et al, 1982
"Better Explanations" in Multiple Sclerosis Diagnostic Workup
Neurol 92:e2527-e2537, Calabrese, M.,et al, 2019
Clemastine Fumarate as a Remyelinating Therapy for Multiple Sclerosis (ReBUILD): A Randomised, Controlled, Double-Blind, Crossover Trial
Lancet 390:2481-2489, Green, A.J.,et al, 2017
Association Between Clinical Conversion to Multiple Sclerosis in Radiologically Isolated Syndrome and Magnetic Resonance Imaging, Cerebrospinal Fluid, and Visual Evoked Potential: Follow-Up of 70 Patients
Arch Neurol 66:841-846, Lebrun,C.,et al, 2009
Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
Ann Neurol 50:121-127, McDonald,W.I.,et al, 2001
Practice Parameter: The Usefulness of Evoked Potentials in Identifying Clinically Silent Lesions in Patients With Suspected Multiple Sclerosis (an Evidence-Based Review)
Neurol 54:1720-1725, Gronseth,G.S.&Ashman,E.J., 2000
Vigabatrin-Associated Retinal Cone System Dysfunction, Electroretinogram & Ophthalmol Findings
Neurol 50:614-618, Krauss,G.L.,et al, 1998
Charcot-Marie-Tooth Neuropathies:From Clinical Description to Molecular Genetics
Muscle & Nerve 18:267-275995., Ionasecu,V.V., 1995
Visual Evoked Potential in Adrenoleukodystrophy:Glycerol Trioleate and Lorenzo Oil
Ann Neurol 34:169-174, 1211993., Kaplan,P.W.,et al, 1993
Intra-arterial Cisplatin-Associated Optic and Otic Toxicity
Arch Neurol 49:83-86, Maiese,K.,et al, 1992
Evoked Potentials in Cerebrotendinous Xanthomatosis and Effect Induced by Chenodeoxycholic Acid
Arch Neurol 49:469-475, Mondelli,M.,et al, 1992
Longitudinal Neurophysiologic Studies in Pt with Metachromatic Leukodystrophy Following Bone Marrow Trnspl
Arch Neurol 49:1088-1092, Dhuna,A.,et al, 1992
Reversal of a Neurologic Paraneoplastic Syndrome with Octreotide (Sandostatin) in a Pt with Glucagonoma
Am J Med 91:434-436, Holmes,A.,et al, 1991
Hallervorden-Spatz Syndrome and Brain Iron Metabolism
Arch Neurol 48:1285-1293, Swaiman,K.F., 1991
Vision and Hearing During Deferoxamine Therapy
J Pediatr 117:326-330, Cohen,A.,et al, 1990
Infantile CNS Spongy Degeneration-14 Cases:Clinical Update
Neurol 40:1876-1882, Gascon,G.G.,et al, 1990
Subacute Combined Degeneration of the Spinal Cord
In Rowland's, Merritt's Textbk of Neurology, Lea & Febiger, Phila, 8th Ed, p. 691, Mancall,E.L., 1989
Visual & Auditory Neurotoxicity in Patients Receiving Subcutaneous Deferoxamine Infusions
NEJM 314:869-873, Olivieri,N.F.,et al, 1986
Visual Evoked Potentials in the Detection of Subclinical Optic Toxic Effects Secondary to Ethambutol
Arch Neurol 40:645-648, Yiannikas,C.,et al, 1983
Visual Evoked Potentials in Occipital Lobe Lesions
Arch Neurol 38:80-85, Streletz,L.J.,et al, 1981
Central Achromatopsia:Behavioral, Anatomic, & Physiologic Aspects
Neurol 30:1064-1071, Damasio,A.,et al, 1980
Clinical Pathological Conference
Adrenoleukodystrophy, with Peripheral Neuropathy, Case Record 18-1979, NEJM 300:1037-104579., , 1979
Toluene Optic Neuropathy
Ann Neurol 4:390, Keane,J.R., 1978
Subclinical Optic Neuropathy in Multiple Sclerosis
Arch Neurol 34:666, Galvin,R.J.,et al, 1977